Somatropin - JCR Pharmaceuticals
Alternative Names: Growject; JR-142; JR-401A; JR-401S; JR-401X; Redalsomatropin alfa - JCR Pharmaceuticals; Somatropin-long-acting - JCR PharmaceuticalsLatest Information Update: 25 Dec 2024
At a glance
- Originator JCR Pharmaceuticals; Savient Pharmaceuticals
- Developer JCR Pharmaceuticals
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Short stature; Somatotropin deficiency
- No development reported Growth disorders